Our September meeting continued virtual by member preference.

Beacon members entertained a new funding proposal from Vincere Biosciences, which is developing small molecule therapeutics targeting mitochondrial quality control to cure age-related and neurodegenerative diseases.

Members reported on companies in due diligence consisting of:

• Ocular Technologies, and
• RevMedica.

We heard updates on new or renewed funding rounds for: